Rules on gene therapy are tightened after leukaemia alertBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7368.791/a (Published 12 October 2002) Cite this as: BMJ 2002;325:791
- Sally Hargreaves
The UK Department of Health's gene therapy advisory committee (GTAC) has this week recommended that additional measures be put in place to protect patients undergoing gene therapy trials.
This comes in response to the suspension of gene therapy trials at Necker Hospital, Paris, when a boy being treated for X linked severe combined immunodeficiency syndrome (SCID) developed leukaemia.
The committee was alerted to the case on 16 September and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial